{"id":38625,"date":"2026-07-17T06:00:00","date_gmt":"2026-07-17T04:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7b67d44da837081dc59a56a29a81079c"},"modified":"2026-07-17T06:00:00","modified_gmt":"2026-07-17T04:00:00","slug":"meiji-seika-pharma-results-from-the-global-phase-iii-trial-integral-2-of-nacubactam-a-novel-%ce%b2-lactamase-inhibitor-highlighted-in-the-lancet-microbes-coverage-of-escmid-global-congre","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=38625","title":{"rendered":"Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel \u03b2-Lactamase Inhibitor, Highlighted in The Lancet Microbe\u2019s Coverage of ESCMID Global Congress 2026"},"content":{"rendered":"

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel \u03b2-lactamase inhibitor, were highlighted in The Lancet Microbe<\/i>\u2019s coverage<\/a> of ESCMID Global Congress 2026 (held in Munich, Germany).<\/p><\/a><\/a>

\nAs highlighted in The Lancet Microbe<\/i>\u2019s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows:<\/p>

\nThe Integral-2 study (jRCT2031230076<\/a>) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter<\/i> species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatment success at seven days after the end of treatment, cefepime\/nacubactam and aztreonam\/nacubactam showed success rates of 44.4% (12\/27 patients) and 50.0% (12\/24 patients), respectively; for reference, the success rate with Best Available Therapy (BAT) was 26.1% (6\/23 patients). No major clinical safety concerns were observed.<\/p>

\nFor background, nacubactam is a \u03b2-lactamase inhibitor intended for use in combination with cefepime or aztreonam for infections caused by Gram-negative bacteria resistant to carbapenems. Based on the results of two Phase III global studies\u2014the Integral-1 study (enrolling patients with complicated urinary tract infections and acute uncomplicated pyelonephritis; jRCT2031230075<\/a>) and the Integral-2 study (enrolling patients with infections caused by carbapenem-resistant Enterobacterales [CRE]; jRCT2031230076<\/a>)\u2014Meiji Seika Pharma submitted a New Drug Application (NDA) in Japan in December 2025.<\/p>

\nMeiji Seika Pharma is committed to contributing to the fight against antimicrobial resistance (AMR), a global issue known as the silent pandemic.<\/p>

\nAbout Nacubactam (Development Code: OP0595):\n<\/b>Nacubactam is a novel \u03b2-lactamase inhibitor developed by Meiji Seika Pharma. When used in combination with approved \u03b2-lactam antibiotics, it is expected to be effective against CRE. This mechanism restores the antimicrobial activity of \u03b2-lactam antibiotics against CRE. Additionally, OP0595 inhibits penicillin-binding protein 2 (PBP2), an enzyme involved in the biosynthesis of peptidoglycan, a key component of bacterial cell walls. This additional mechanism enhances the antimicrobial activities of \u03b2-lactam antibiotics against CRE. This dual mechanism differentiates it from existing \u03b2-lactamase inhibitors.<\/p>

\nReferences:\n<\/i><\/b>Venkatesan P. ESCMID Global Congress 2026. The Lancet Microbe. 2026:101476.<\/a><\/p> Contacts<\/b>

\nFor further information:\nMeiji Seika Pharma Co., Ltd.\nHayato Okade\nProject Manager, Nacubactam\npr-pharma@meiji.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a n…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-38625","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/38625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38625"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/38625\/revisions"}],"predecessor-version":[{"id":38626,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/38625\/revisions\/38626"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}